Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Status:
Completed
Trial end date:
2020-10-04
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to demonstrate the superior efficacy versus placebo of
OBE2109 alone and in combination with add-back therapy for the reduction of heavy menstrual
bleeding associated with uterine fibroids in premenopausal women.